Hydrogen Therapy Helps Brain Bleeding Patient with Autoimmune Disease
- Authors
- Jing-Yuan Chen, Jeng-Wei Lu, Shao-Wei Feng, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Feng-Cheng Liu
- Journal
- In Vivo
- Year
- 2024
- DOI
- 10.21873/invivo.13799
- Study Type
- Human
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Taiwan
- Health Condition
- Aneurysmal Subarachnoid Hemorrhage
- Body System
- Neurological
TL;DR
A woman with a brain bleed and autoimmune diseases improved after treatment with hydrogen capsules, suggesting a new potential therapy.
Key Finding
A single patient with a severe brain bleed and autoimmune disease showed stabilization of symptoms and improvements in immune markers after receiving daily hydrogen capsules, though this is a case report of one person rather than a controlled study.
Summary
This report describes a single patient with a life-threatening brain bleed (subarachnoid hemorrhage) who also had two autoimmune diseases and a stroke. After standard treatments did not fully help, she received hydrogen capsules daily. Her immune system markers improved, including increases in certain protective immune cells, and a blood test related to her autoimmune disease changed from abnormal to normal. Her symptoms stabilized without reported side effects.
Practical Takeaway
This is a single case report, not a controlled study, so it cannot prove hydrogen therapy works for this condition. While the patient's outcome was positive, case reports describe what happened in one person and cannot establish whether hydrogen caused the improvement or whether it would help others. Much larger and more rigorous studies would be needed before drawing any conclusions about hydrogen's effectiveness for brain bleeds or autoimmune disease.
Abstract
Background/aim: Most nontraumatic subarachnoid hemorrhages (SAHs) are caused by ruptured saccular aneurysms, often resulting in a devastating clinical event characterized by high mortality and significant morbidity among survivors. Numerous studies have confirmed the neuroprotective effects of the molecular hydrogen due to its unique biological properties. Case report: We present the case of a 44-year-old female with aneurysmal SAH with rheumatoid arthritis (RA) and newly diagnosed systemic lupus erythematosus (SLE), complicated by acute ischemic infarction. Despite surgical, pharmacological and non-pharmacological interventions, including embolization of the aneurysm, immunosuppressant, non-vitamin K antagonist oral anticoagulant (NOAC), and plasmapheresis, loss of consciousness continued. The patient began daily treatment with hydrogen capsules, resulting in increased in Treg cells, Breg cells, increased TIM3+ expression on Tc cells, and the conversion of anti-dsDNA from positive to negative. Her clinical symptoms stabilized without adverse effects. Conclusion: This case highlights the potential benefits of molecular hydrogen therapy in managing aneurysmal SAH with underlying autoimmune disease, warranting further research. Keywords: Breg cell; Hydrogen therapy; T regulatory type 1 (Tr1) cells; TIM3; case report; rheumatoid arthritis; subarachnoid hemorrhage; systemic lupus erythematosus.